Related Experiment Video

Updated: Nov 10, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

434

Teduglutide for pediatric short bowel syndrome patients

Beatrice E Rosete1,2, Danielle Wendel3,4, Simon P Horslen3,4

  • 1Department of Pharmacy, Seattle Children's Hospital, Seattle, WA, USA.

Expert Review of Gastroenterology & Hepatology
|April 2, 2021
PubMed

Insights

Teduglutide is a new treatment that helps children with short bowel syndrome (SBS) adapt their intestines. This glucagon-like peptide 2 (GLP-2) analog is safe and effective for pediatric SBS patients over one year old.

Area of Science:

  • Pediatric Gastroenterology
  • Clinical Pharmacology
  • Gastrointestinal Adaptation

Background:

  • Pediatric short bowel syndrome (SBS) management historically focused on complication prevention to allow natural intestinal adaptation.
  • Teduglutide, a glucagon-like peptide 2 (GLP-2) analog, represents a novel therapeutic approach for pediatric SBS.

Purpose of the Study:

  • To review the pharmacology, safety, efficacy, and tolerability of teduglutide in pediatric patients (age >1 year) with SBS.
  • To discuss the current evidence and clinical role of teduglutide in managing pediatric SBS.

Main Methods:

  • Comprehensive review of existing studies on teduglutide in pediatric SBS patients.
  • Analysis of pharmacological data, safety profiles, efficacy outcomes, and tolerability assessments.

Main Results:

  • Teduglutide is the first approved pharmacological agent shown to safely and effectively augment intestinal adaptation in pediatric SBS.
  • Clinical studies demonstrate positive outcomes in terms of efficacy and tolerability in the target population.

Conclusions:

  • Teduglutide offers a significant advancement in the medical management of pediatric SBS, enhancing the natural adaptation process.
  • Further research and development are warranted to optimize teduglutide's use and explore its potential in broader pediatric populations.

Keywords:
Short bowel syndromegattexglp-2 analogueglucagon-like peptide 2 analoguepediatricsrevestiveteduglutide

More Related Videos

Tissue Engineering of the Intestine in a Murine Model08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

15.2K
Small Bowel Transplantation In Mice36:30

Small Bowel Transplantation In Mice

Published on: August 20, 2007

14.8K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
278
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
447
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
485
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
291
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
411
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
280